首页> 美国卫生研究院文献>other >First-in-human Phase I study of Pictilisib (GDC-0941) a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in patients with advanced solid tumors

【2h】

First-in-human Phase I study of Pictilisib (GDC-0941) a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in patients with advanced solid tumors

机译：Pictilisib（GDC-0941）是晚期实体瘤患者的第一个人类第一阶段研究Pictilisib是一种有效的泛I类磷脂酰肌醇3-激酶（PI3K）抑制剂。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeThis first-in-human dose-escalation trial evaluated the safety, tolerability, maximal tolerated dose (MTD), dose limiting toxicities (DLTs), pharmacokinetics, pharmacodynamics and preliminary clinical activity of pictilisib (GDC-0941), an oral, potent and selective inhibitor of the Class I phosphatidylinositol-3-kinases (PI3K).

机译：目的这项首次人类剂量递增试验评估了Pictilisib（GDC-0941）的安全性，耐受性，最大耐受剂量（MTD），剂量极限毒性（DLT），药代动力学，药效学和初步临床活性（GDC-0941） I类磷脂酰肌醇3-激酶（PI3K）的选择性抑制剂。

著录项

期刊名称 other
作者
Debashis Sarker; Joo Ern Ang; Richard Baird; Rebecca Kristeleit; Krunal Shah; Victor Moreno; Paul A. Clarke; Florence I. Raynaud; Gallia Levy; Joseph A Ware; Kathryn Mazina; Ray Lin; Jenny Wu; Jill Fredrickson; Jill M Spoerke; Mark R Lackner; Yibing Yan; Lori S. Friedman; Stan B. Kaye; Mika K. Derynck; Paul Workman; Johann S. de Bono;
展开▼
作者单位

展开▼
年(卷),期 -1(21),1
年度 -1
页码 77–86
总页数 19
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors [J] . Sarker Debashis, Ang Joo Ern, Baird Richard, Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第1期

机译：晚期实体瘤患者Pictilisib（GDC-0941）是一种有效的泛I类磷脂酰肌醇3-激酶（PI3K）抑制剂的首次人类I期研究。
2. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors [J] . Ecological restoration . 2020,第2期

机译：MEK抑制剂COBIMETINIB（GDC-0973）与PI3K抑制剂Pictilisib（GDC-0941）的相位IB研究在先进的实体瘤患者中
3. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies [J] . Munster Pamela, Aggarwal Rahul, Hong David, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第8期

机译：口服泛I类磷脂酰肌醇3激酶抑制剂GSK2126458在晚期实体瘤恶性肿瘤中的人类首次I期研究
4. Development of an Efficient Solid-Phase Synthetic Methodology to Construct a Combinatorial Library of a Potent HDAC Inhibitor [C] . Salvatore DiMaro, Jung-Mo Ann American Peptide Symposium . 2009

机译：开发有效的固相合成方法，构建有效的HDAC抑制剂的组合库
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. First-in-human phase I study of copanlisib (BAY 80-6946) an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor in patients with advanced solid tumors and non-Hodgkins lymphomas [O] . A. Patnaik, L. J. Appleman, A. W. Tolcher, -1

机译：潘诺昔布（BAY 80-6946）的人类首次I期研究（静脉注射泛I类磷脂酰肌醇3激酶抑制剂）用于晚期实体瘤和非霍奇金淋巴瘤患者
7. First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors [O] . Sarker, Debashis, Ang, Joo Ern, Baird, Richard, 2015

机译：晚期实体瘤患者Pictilisib（GDC-0941）是一种有效的泛I类磷脂酰肌醇3-激酶（PI3K）抑制剂的首次人类I期研究。

First-in-human Phase I study of Pictilisib (GDC-0941) a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in patients with advanced solid tumors

摘要

著录项

相似文献

相关主题

期刊订阅